U.S. FDA Accepts Allergan's New Drug Application for Bimatoprost Sustained-Release in Patients with Open-Angle Glaucoma or Ocular Hypertension

Filing included data from the Phase 3 ARTEMIS studies, which demonstrated that the majority of patients remained treatment free for at least 1 year following 3 treatments with Bimatoprost Sustained-Release Allergan continues advancement in eye care inno... Biopharmaceuticals, Ophthalmology, FDA Allergan, Bimatoprost, intraocular pressure
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news